George Lau, MD, FRCP, FAASLD, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects seen with the STRIDE regimen in the phase 3 HIMALAYA trial.
George Lau, MD, FRCP, FAASLD
Advertisement
Articles by George Lau, MD, FRCP, FAASLD
George Lau, MD, FRCP, FAASLD, discusses the association between immune-related adverse effects and overall survival for patients with unresectable hepatocellular carcinoma enrolled on the phase 3 HIMALAYA trial.
Advertisement
Latest Updated Articles
Dr Lau on the Association of irAEs and OS in the HIMALAYA Study in HCCPublished: June 28th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5